# AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

> **NCT00305656** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Recurrent Adult Brain Tumor

## Interventions

- **DRUG:** cediranib maleate

## Key facts

- **NCT ID:** NCT00305656
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2012-04
- **Final completion:** —
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2013-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00305656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00305656, "AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00305656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*